Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Acumen Pharmaceuticals

Clinical trials sponsored by Acumen Pharmaceuticals, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New drug sabirnetug aims to slow Alzheimer's decline Results expected Oct 2026 (estimated)

Browse trials soon ready across all sponsors →

Not yet finished but already full! 1

New drug sabirnetug aims to slow Alzheimer's decline

Disease control Ongoing

This Phase 2 trial tests whether sabirnetug, given as an IV infusion every four weeks, can slow cognitive and functional decline in people with early Alzheimer's disease. About 542 participants will receive either sabirnetug or a placebo. The main outcome is change in a combined …

Phase 2 • Sponsor: Acumen Pharmaceuticals • Aim: Disease control

Last updated Jun 27, 2026 07:55 UTC